|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0030705,
umls-concept:C0033860,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0065767,
umls-concept:C0087111,
umls-concept:C0205081,
umls-concept:C0205082,
umls-concept:C0205390,
umls-concept:C0358518,
umls-concept:C1122087,
umls-concept:C2603343
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2010-7-29
|
|
pubmed:abstractText |
Data are lacking on the use of topical therapies in combination with tumour necrosis factor blockers for the treatment of psoriasis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Betamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Calcitriol,
http://linkedlifedata.com/resource/pubmed/chemical/Dermatologic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/adalimumab,
http://linkedlifedata.com/resource/pubmed/chemical/calcipotriene
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1365-2133
|
|
pubmed:author |
pubmed-author:ArenbergerPP,
pubmed-author:ChimentiSS,
pubmed-author:EsslingerH-UHU,
pubmed-author:GhislainP-DPD,
pubmed-author:KhemisAA,
pubmed-author:KragballeKK,
pubmed-author:KupperHH,
pubmed-author:OrtonneJ-PJP,
pubmed-author:SauratJ-HJH,
pubmed-author:SprøgelPP,
pubmed-author:ThaçiDD,
pubmed-author:UnnebrinkKK
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
163
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
402-11
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20377585-Administration, Topical,
pubmed-meshheading:20377585-Adult,
pubmed-meshheading:20377585-Anti-Inflammatory Agents,
pubmed-meshheading:20377585-Antibodies, Monoclonal,
pubmed-meshheading:20377585-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20377585-Betamethasone,
pubmed-meshheading:20377585-Calcitriol,
pubmed-meshheading:20377585-Dermatologic Agents,
pubmed-meshheading:20377585-Double-Blind Method,
pubmed-meshheading:20377585-Drug Therapy, Combination,
pubmed-meshheading:20377585-Europe,
pubmed-meshheading:20377585-Female,
pubmed-meshheading:20377585-Humans,
pubmed-meshheading:20377585-Male,
pubmed-meshheading:20377585-Medication Adherence,
pubmed-meshheading:20377585-Middle Aged,
pubmed-meshheading:20377585-Psoriasis,
pubmed-meshheading:20377585-Severity of Illness Index
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study.
|
|
pubmed:affiliation |
Department of Dermatology, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany. thaci@em.uni-frankfurt.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
